{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-083722","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.467597+00:00","generated_at":"2026-05-31T15:28:44.992270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Merck Q2 2024: revenue $16.1B (+7% YoY); raises sales outlook but lowers EPS guidance on EyeBio charge","bullets":["Q2 revenue $16.1B (+7% YoY, +11% ex-FX); GAAP EPS $2.14, Non-GAAP EPS $2.28; KEYTRUDA sales $7.3B (+16%).","Full-year 2024 sales outlook raised to $63.4-64.4B (from $63.1-64.3B); Non-GAAP EPS guidance lowered to $7.94-8.04 (from $8.53-8.65) due to $1.3B EyeBio acquisition charge.","WINREVAIR generated $70M in Q2 sales; over 1,000 patients treated since U.S. launch in March 2024.","Completed acquisitions of EyeBio and Elanco's Aqua Business in July 2024; $0.51/share EPS impact from EyeBio.","CDC's ACIP unanimously recommended CAPVAXIVE; positive EU CHMP opinion for WINREVAIR in PAH."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-083722","json":"https://secwatch.observer/filing/0001104659-24-083722.json","markdown":"https://secwatch.observer/filing/0001104659-24-083722.md","text":"https://secwatch.observer/filing/0001104659-24-083722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465924083722/0001104659-24-083722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465924083722/tm2420272d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:28:44.992270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}